

[Roche expands portfolio with adenovirus test](#)

written by CAP TODAY

March 19, 2020

March 2020—Roche announced the commercial availability of a quantitative Adenovirus Test for use with the Cobas Omni utility channel on the Cobas 6800/8800 systems in countries accepting the CE mark. The test aims to help health care professionals better monitor and manage severely immunocompromised transplant patients at risk of infections.

The Adenovirus Test is based on real-time PCR and provides quantitative accuracy for detection and quantification of human adenovirus. The assay calibrators are traceable to the World Health Organization international standard for adenovirus and reports in international units per milliliter. The test is designed to minimize variability and complexity in testing, offering an alternative to lab-developed tests.

The Cobas Omni utility channel on the Cobas 6800/8800 systems enables a broader testing menu by consolidating open channel assays with Roche in vitro assays on a single platform. Open channel assays may include IVD assays as well as routine lab-developed tests.

[Roche](#), 317-521-2000



©2026 CAP TODAY, all rights reserved.